A MAGE‐A1 peptide is recognized on HLA‐B7 human tumors by cytolytic T lymphocytes

Luiten, Rosalie M.; Bruggen, Pierre van der

doi:10.1034/j.1399-0039.2000.550206.x

Cited by 20 publications

(12 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4). This is higher than for the previously identified MAGE antigenic peptides, for which values ranging from 0.05 to 100 nM were observed (22, 25–28). The MAGE‐4b peptide, EVDPTSNTY, was not recognized by clone D10 (data not shown).…”

Section: Resultscontrasting

confidence: 64%

New MAGE‐4 antigenic peptide recognized by cytolytic T lymphocytes on HLA‐A1 tumor cells

et al. 2003

Self Cite

View full text Add to dashboard Cite

'Cancer-germline' genes such as those of the MAGE family are expressed in many tumors and in male germline cells, but are silent in other normal tissues. They encode shared tumor-specific antigens, which have been used in small therapeutic vaccination trials of cancer patients. Gene MAGE-4, which is expressed in more than 50% of carcinomas of esophagus, head and neck, lung, and bladder, has two known alleles. Using PCR amplifications and digestions of the amplified product, we found that one third of the MAGE-4-positive samples expressed MAGE-4a. We folded HLA-A1 tetramers with peptide MAGE-4a169-177 EVDPASNTY, which is homologous to MAGE-1- and MAGE-3-encoded peptides recognized on HLA-A1 by cytolytic T lymphocytes. Blood lymphocytes from an individual without cancer were directly labelled with these A1/MAGE-4 tetramers. The very rare cells that were stained were sorted by flow cytometry and cloned. We isolated a cytolytic T-lymphocyte clone that lyzed specifically cells pulsed with this MAGE-4 peptide and HLA-A1 tumor cells expressing MAGE-4a, demonstrating that this antigenic peptide is processed efficiently in tumor cells. This peptide might therefore be useful for therapeutic antitumoral vaccination.

show abstract

Section: Resultscontrasting

confidence: 64%

New MAGE‐4 antigenic peptide recognized by cytolytic T lymphocytes on HLA‐A1 tumor cells

et al. 2003

Self Cite

View full text Add to dashboard Cite

show abstract

“…3B). This is within the range of the previously identified MAGE antigenic peptides, for which values ranging from 0.05 to 100 nM were observed (18,21–24). These two peptides are encoded by both MAGE‐A4a and MAGE‐A4b .…”

Section: Resultssupporting

confidence: 86%

A MAGE‐A4 peptide presented by HLA‐B37 is recognized on human tumors by cytolytic T lymphocytes

Zhang

Stroobant

Russo³

et al. 2002

Tissue Antigens

Self Cite

View full text Add to dashboard Cite

'Cancer-germline' genes such as those of the MAGE family are expressed in many tumors and in male germline cells, but are silent in normal tissues. They encode shared tumor-specific antigens, which have been used in therapeutic vaccination trials of cancer patients. MAGE-A4 is expressed in more than 50% of carcinomas of esophagus, head and neck, lung, and bladder. We report here the identification of a new MAGE-A4 encoded peptide, which is recognized by a cytolytic T lymphocyte (CTL) clone on HLA-B*3701. The sequence of the peptide is SESLKMIF. It corresponds to the MAGE-A4156-163 protein sequence. When tumor cells expressing MAGE-A4 were transfected with HLA-B*3701, they were recognized by the CTL clone, demonstrating that the peptide ought to be processed in tumor cells and could therefore serve as a target for therapeutic antitumoral vaccination.

show abstract

“…We are using now another “reverse immunology” strategy: dendritic cells transduced with gene MAGE‐3 are used as stimulator cells for autologous T lymphocytes obtained from non‐cancerous blood donors (12, 13). This has already resulted in the identification of several MAGE epitopes (12–15). We describe here the identification of a new MAGE‐3 epitope, using the same method.…”

mentioning

confidence: 99%

A MAGE‐3 peptide recognized on HLA‐B35 and HLA‐A1 by cytolytic T lymphocytes

et al. 2001

Self Cite

View full text Add to dashboard Cite

Antigens encoded by MAGE genes are of particular interest for cancer immunotherapy because of their strict tumoral specificity and because they are shared by many tumors. Antigenic peptide EVDPIGHLY encoded by MAGE-3 and known to be presented by HLA-A*0101 is currently being used in therapeutic vaccination trials. We report here that a cytolytic T-lymphocyte (CTL) clone, which is restricted by HLA-B*3501, recognizes the same peptide and, importantly, lyses HLA-B*3501 tumor cells expressing MAGE-3. These results infer that the current clinical use of peptide EVDPIGHLY can now be extended to HLA-B*3501 patients.

show abstract

A MAGE‐A1 peptide is recognized on HLA‐B7 human tumors by cytolytic T lymphocytes

Cited by 20 publications

References 19 publications

New MAGE‐4 antigenic peptide recognized by cytolytic T lymphocytes on HLA‐A1 tumor cells

New MAGE‐4 antigenic peptide recognized by cytolytic T lymphocytes on HLA‐A1 tumor cells

A MAGE‐A4 peptide presented by HLA‐B37 is recognized on human tumors by cytolytic T lymphocytes

A MAGE‐3 peptide recognized on HLA‐B35 and HLA‐A1 by cytolytic T lymphocytes

Contact Info

Product

Resources

About